MedTrace Logo

Elements of Adaptive Immunity in Epithelial Ovarian Cancer

NCT07528911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 687

Last updated 2026-07-27

No results posted yet for this study

Summary

The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.

Conditions

  • Epithelial High Grade Serous Ovarian Cancer

Interventions

OTHER

Assessment of elements of adaptive immunity in tumor biopsies

Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated at tumor biopsies of patients with advanced ovarian cancer treated with chemotherapy.

Sponsors & Collaborators

  • Attikon Hospital

    collaborator OTHER

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-04-01
Completion
2025-06-22

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07528911 on ClinicalTrials.gov